查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032699

抗結核治療市場報告：按疾病類型、診斷和治療、最終用戶和地區分類（2026-2034 年）

Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球抗結核藥物市場規模達16.151億美元。展望未來，IMARC Group預測，到2034年，市場規模將達到26.153億美元，2026年至2034年的複合年成長率為5.34%。醫療保健支出不斷成長、有利的報銷政策、技術進步以及不斷擴大的公私合營是推動市場成長的主要因素。

抗結核藥物是指用於治療結核病（TB）的藥物和治療策略。結核病是由結核分枝桿菌引起的細菌感染疾病。結核病主要侵襲肺部，但也可擴散至身體其他部位，包括腎臟、脊椎和腦部。抗結核藥物用於清除體內的結核分枝桿菌，並防止感染擴散。這通常透過合併使用抗生素來實現，療程為6至9個月。最常使用的藥物包括異煙肼、利福平、乙胺丁醇和Pyrazinamide。特定的藥物組合取決於感染的嚴重程度和患者的健康狀況。此外，定期監測和後續觀察對於確保治療成功和預防抗藥性結核病的發生至關重要。全球結核病（TB）的高發生率，尤其是在中低收入國家，是推動市場發展的主要因素之一。此外，由於治療不徹底、醫療基礎設施不足以及缺乏足夠的醫療保健，抗藥性結核病的發生率不斷上升，這對結核病藥物市場的成長產生了積極影響。

抗結核藥物市場趨勢：

製藥領域的進展

近年來，抗結核藥物備受關注，因為它們也涵蓋了氧氣療法、營養支持和潛在併發症管理等輔助療法。因此，新藥和治療策略的研發為參與企業創造了新的成長機會。近年來，貝達喹啉和德拉馬尼等幾種治療結核病的新藥已獲核准。與傳統抗結核藥物相比，這些藥物在療效和安全性方面均有所改善。同時，技術和診斷方法的進步使得結核病的早期發現和診斷成為可能，從而能夠及時啟動治療並改善患者的預後。

醫療保健成本上漲和政府支持

尤其值得注意的是，新興經濟體醫療保健支出的成長正在改善醫療基礎設施，並提高民眾獲得高品質醫療服務（包括結核病治療）的機會。此外，大眾對結核病的認知不斷提高，以及對早期診斷和治療重要性的理解不斷加深，也促進了抗結核藥物需求的成長。同時，政府對結核病控制計畫的投入和資金支持在推動抗結核藥物市場成長方面發揮著至關重要的作用。例如，各國政府和非政府組織正在攜手合作，加強宣傳活動，改善診斷技術，並確保民眾能夠獲得價格合理且有效的治療，預計這將推動未來幾年市場的成長。

研究與開發活動迅速增加

研發舉措的增加正在提升市場潛力。這些活動可望為市場成長創造可觀的機會。此外，新藥認證的增加以及現有藥物的改進將進一步刺激市場需求。糖尿病新型高效治療方法的出現以及早期診斷技術的進步也將為市場帶來機會。新興市場對新治療方法研發投入的增加以及抗結核藥物使用量的不斷成長，將在預測期內為市場提供更多成長機會。

本報告解答的主要問題

  • 迄今為止，全球抗結核藥物市場的發展趨勢是什麼？您預計未來幾年該市場將如何發展？
  • 全球抗結核藥物市場的促進因素、限制因素和機會是什麼？
  • 各種促進因素​​、阻礙因素和機會如何影響全球抗結核藥物市場？
  • 主要區域市場有哪些？
  • 哪個國家對結核病藥物的需求市場最大？
  • 按疾病類型分類的市場組成是什麼？
  • 在抗結核藥物市場中，哪種疾病類型最受關注？
  • 按診斷和治療方式分類的市場區隔如何？
  • 在抗結核藥物市場中，哪種診斷和治療方法最具吸引力？
  • 依最終用戶分類的市場區隔如何？
  • 在抗結核藥物市場中，哪一種終端使用者最具吸引力？
  • 全球抗結核藥物市場的競爭格局如何？
  • 全球抗結核藥物市場的主要參與者/公司有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球抗結核藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疾病類型分類

  • 活動性肺結核
  • 潛伏性結核病
  • 其他

第7章 市場區隔：依診斷及治療分類

  • 診斷
    • 主要部分
      • 驗血
      • 影像檢查
      • 痰液檢查
      • 其他
  • 治療
    • 主要部分
      • 一線藥物
        • 主要類型
          • 異煙肼
          • 乙胺布托
          • 利福平
          • 其他
      • 二線治療藥物
        • 主要類型
          • 奇塞他宗
          • 對氨基水楊酸（PAS）
          • 其他
      • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 專科診所
  • 居家照護
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：促進、抑制與機遇

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
Product Code: SR112026A7629

The global anti-tuberculosis therapeutics market size reached USD 1,615.1 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 2,615.3 Million by 2034, exhibiting a growth rate (CAGR) of 5.34% during 2026-2034. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the anti-tuberculosis therapeutics market growth.

ANTI-TUBERCULOSIS THERAPEUTICS MARKET TRENDS:

Advancements in Drugs

In recent years, anti-tuberculosis therapeutics have gained traction as they also involve supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise. Consequently, the development of new drugs and treatment strategies is creating new growth opportunities for the market participants. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of tuberculosis. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of tuberculosis, leading to timely initiation of treatment and better patient outcomes.

Increasing Healthcare Spending and Government Support

The increasing healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment have also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Surge in R&D Activities

An uptick in the number of research and development initiatives is augmenting the market potential. Such activities are expected to offer lucrative opportunities for market growth. Moreover, the increasing number of new drug approvals and drug enhancement will further fuel the market demand. The emergence of new and more effective treatments for diabetes and early disease diagnosis is also opportunistic for the market. Growth in investments for the development of novel treatments and an increase in the adoption of anti-tuberculosis therapeutics in emerging markets will further present opportunities for growth during the forecast period.

KEY MARKET SEGMENTATION:

Disease Type Insights:

  • Active TB
  • Latent TB
  • Others

The anti-tuberculosis therapeutics market report has provided a detailed breakup and analysis of the market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

  • Diagnosis
    • Blood Tests
    • Imaging Tests
    • Sputum Tests
    • Others
  • Treatment
    • First-Line of Drugs Isoniazid Ethambutol Rifampin Others
    • Second-Line of Drugs Thiacetazone Paraaminosalicyclic Acid (PAS) Others
    • Others
  • First-Line of Drugs
    • Isoniazid
    • Ethambutol
    • Rifampin
    • Others
  • Second-Line of Drugs
    • Thiacetazone
    • Paraaminosalicyclic Acid (PAS)
    • Others

End User Insights:

  • Hospitals
  • Specialty Clinics
  • Homecare

Regional Insights:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti- tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

  • F Hoffmann-La Roche Ltd.
  • Lannett Company Inc.
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Otsuka Pharmaceutical Co. Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years ?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market ?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market ?
  • What are the key regional markets ?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the disease type ?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on the diagnosis and treatment ?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market ?
  • What is the breakup of the market based on end user ?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market ?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market ?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
        • 7.2.2.1.1 Major Types
          • 7.2.2.1.1.1 Isoniazid
          • 7.2.2.1.1.2 Ethambutol
          • 7.2.2.1.1.3 Rifampin
          • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
        • 7.2.2.2.1 Major Types
          • 7.2.2.2.1.1 Thiacetazone
          • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
          • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2025
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2025
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2025
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million USD), 2026-2034
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players